RESUMO
This retrospective study included 63 patients with obesity (Body Mass Index; BMI ≥ 30) and psoriasis. Our aim was to verify the effectiveness of different systemic therapies administered to the above cohort of subjects over a period of 1 year. Improvements of 75%, 90%. and 100% compared with the baseline Psoriasis Area Severity Index (PASI 75, PASI 90, and PASI 100, respectively) were used as clinical outcome measures. In a median time of 16 weeks, 85.7%, 68.2%, and 38.0% of patients achieved PASI 75, PASI 90, and PASI 100, respectively. In parallel, the Dermatology Life Quality Index (DLQI) and the visual analog score for measuring itch intensity (VAS itch) decreased significantly (P<0.0001 for both parameters). At the achievement of PASI 75, BMI increased as compared to baseline (P=0.02) and did not significantly vary at the attainment of PASI 90 and PASI 100 (P= 0.07 for both outcomes). Logistic multivariate regression analysis showed that treatment with biologic drugs was a positive predictor for achieving PASI 75, PASI 90, and PASI 100. BMI >31.7 and the presence of psoriatic arthritis were negative predictors for the achievement of PASI 90, while having a DLQI >6 was a positive predictor.
